Bioengineering of BRAF and COX2 inhibitor nanogels to boost the immunotherapy of melanoma via pyroptosis

A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance

(2022) Alexander C. Huang et al.   NATURE IMMUNOLOGY

Engineered nanogels simultaneously implement HDAC inhibition and chemotherapy to boost antitumor immunity via pyroptosis

(2022) De-Run Chen et al.   Applied Materials Today

Stepwise Size Shrinkage Cascade‐Activated Supramolecular Prodrug Boosts Antitumor Immunity by Eliciting Pyroptosis

(2022) Meng‐Yun Liang et al.   Advanced Science

Uveal melanoma

(2020) Martine J. Jager et al.   Nature Reviews Disease Primers

K27-linked ubiquitination of BRAF by ITCH engages cytokine response to maintain MEK-ERK signaling

(2019) Qing Yin et al.   Nature Communications

Host–Guest Interactions Initiated Supramolecular Chitosan Nanogels for Selective Intracellular Drug Delivery

(2019) Yuan-Fu Ding et al.   ACS Applied Materials & Interfaces

Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis

(2019) Dan A. Erkes et al.   Cancer Discovery

Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin

(2017) Yupeng Wang et al.   NATURE

Cleavage of DFNA5 by caspase-3 during apoptosis mediates progression to secondary necrotic/pyroptotic cell death

(2017) Corey Rogers et al.   Nature Communications

Myeloid derived suppressor cells—An overview of combat strategies to increase immunotherapy efficacy

(2015) Oana Draghiciu et al.   OncoImmunology

Immune-Based Antitumor Effects of BRAF Inhibitors Rely on Signaling by CD40L and IFN 

(2014) P.-C. Ho et al.   CANCER RESEARCH

Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma

(2014) Deborah JL Wong et al.   Molecular Cancer

Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B-Raf-Driven Tumors

(2013) Tara R. Rheault et al.   ACS Medicinal Chemistry Letters

Targeting Oncogenic Drivers and the Immune System in Melanoma

(2012) Grant A. McArthur et al.   JOURNAL OF CLINICAL ONCOLOGY

Simultaneous Targeting of COX-2 and AKT Using Selenocoxib-1-GSH to Inhibit Melanoma

(2012) R. Gowda et al.   MOLECULAR CANCER THERAPEUTICS

Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma

(2011) James S. Wilmott et al.   CLINICAL CANCER RESEARCH

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

(2010) Poulikos I. Poulikakos et al.   NATURE